Phase I Trial to Evaluate the Safety of Intralesional Nivolumab Therapy for Limited Cutaneous Kaposi Sarcoma

By afschroeder • July 15, 2025

Wang CJ, Bang A, Chowdhury S, Leslie KS, Lang UE, Shimoda M, Henrich TJ, Hoh R, Deeks SG, Wang C, Deitchman AN, Couey P, Maurer T. Phase I Trial to Evaluate the Safety of Intralesional Nivolumab Therapy for Limited Cutaneous Kaposi Sarcoma. JCO Oncol Adv. 2025 Jul 7;2(1):e2400098. doi: 10.1200/OA-24-00098. PMID: 40655531; PMCID: PMC12244976.

Tags: Dermatology, Publications, Resident

Temporal CRAC channel blockade modulates the MYC-MXD axis to attenuate autoimmune inflammation

Wu B, Hasiakos S, Cokus S, Do M, Kaplan E, Pellegrini M, Sun Z, Kim RH, Srikanth S, Gwack Y. Temporal CRAC channel blockade modulates[...]

Early and Maintained Treat-to-Target Response with Ixekizumab up to 5 Years in Moderate-to-Severe Psoriasis: Analysis of the UNCOVER-3 Study

Armstrong A, Merola JF, Chughtai R, Fotiou K, Ngantcha M, Sabatino S, Megna M, Man X, Honma M, Carrascosa JM, Pinter A. Early and Maintained[...]

Letter: Patch Test Utilization by Provider Type in the U.S. Commercially Insured Population, 2014-2024: Dermatologists on the Decline

Smart K, Armstrong AW, Adler BL. Letter: Patch Test Utilization by Provider Type in the U.S. Commercially Insured Population, 2014-2024: Dermatologists on the Decline. Dermatitis. 2026 Sep[...]